Structures by: Ayala A. P.
Total: 42
C18H15NO5
C18H15NO5
Journal of natural products (2019) 82, 7 1831-1838
a=13.8289(6)Å b=6.8772(3)Å c=16.9481(7)Å
α=90° β=108.007(2)° γ=90°
C17H15NO5,2(H2O)
C17H15NO5,2(H2O)
Journal of natural products (2019) 82, 7 1831-1838
a=7.5548(16)Å b=9.708(2)Å c=13.168(3)Å
α=104.560(6)° β=100.175(7)° γ=107.218(7)°
Na Ca Mg2 F7
CaF7Mg2Na
Journal of Solid State Chemistry (2004) 177, 2943-2950
a=10.261Å b=10.261Å c=10.261Å
α=90° β=90° γ=90°
C7H3Cl2O2,C3H10NO
C7H3Cl2O2,C3H10NO
CrystEngComm (2017)
a=12.27690(10)Å b=8.00180(10)Å c=26.0006(2)Å
α=90° β=90° γ=90°
C10H13Cl2NO3
C10H13Cl2NO3
CrystEngComm (2017)
a=12.20170(10)Å b=7.959Å c=25.92590(10)Å
α=90° β=90° γ=90°
C10H13Cl2NO3
C10H13Cl2NO3
CrystEngComm (2017)
a=12.24030(10)Å b=7.97880(10)Å c=25.9695(2)Å
α=90° β=90° γ=90°
C7H3Cl1.98O2,C3H10NO
C7H3Cl1.98O2,C3H10NO
CrystEngComm (2017)
a=12.12852(10)Å b=7.92362(7)Å c=25.81707(18)Å
α=90° β=90° γ=90°
C6H9N3O,O4S,0.5(H2O)
C6H9N3O,O4S,0.5(H2O)
CrystEngComm (2016) 18, 34 6378
a=6.9562(3)Å b=19.7321(8)Å c=13.4459(6)Å
α=90° β=93.4175(13)° γ=90°
C6H8N3O,Br
C6H8N3O,Br
CrystEngComm (2016) 18, 34 6378
a=6.6307(4)Å b=16.3280(13)Å c=7.4836(5)Å
α=90° β=92.183(7)° γ=90°
C6H9N3O1,O4S
C6H9N3O1,O4S
CrystEngComm (2016) 18, 34 6378
a=7.3259(2)Å b=6.3982(2)Å c=19.5779(7)Å
α=90° β=98.2460(10)° γ=90°
C24H27NO7,H2O
C24H27NO7,H2O
Journal of natural products (2019) 82, 7 1831-1838
a=8.6893(3)Å b=15.2942(6)Å c=16.9431(6)Å
α=90° β=90° γ=90°
Benzoylmetronidazole--fumaric acid (2/1)
2(C13H13N3O4),C4H4O4
Acta Crystallographica Section C (2019) 75, 5
a=9.0358(5)Å b=26.6419(14)Å c=6.8796(3)Å
α=90° β=102.419(2)° γ=90°
Benzoylmetronidazole—–β-naphthol (1/1)
C13H13N3O4,C10H8O
Acta Crystallographica Section C (2019) 75, 5
a=8.5105(8)Å b=22.387(2)Å c=11.7752(11)Å
α=90° β=108.664(4)° γ=90°
Benzoylmetronidazole--benzoic acid (1/1)
C13H13N3O4,C7H6O2
Acta Crystallographica Section C (2019) 75, 5
a=13.5997(6)Å b=9.0354(4)Å c=16.5974(8)Å
α=90° β=108.646(2)° γ=90°
Benzoylmetronidazole--4-methoxybenzoic acid (1/1)
C13H13N3O4,C8H8O3
Acta Crystallographica Section C (2019) 75, 5
a=9.1309(4)Å b=11.1274(4)Å c=11.8538(5)Å
α=107.3650(10)° β=103.2700(10)° γ=110.0910(10)°
Benzoylmetronidazole--3,5-dinitrobenzoic acid (1/1)
C13H13N3O4,C7H4N2O6
Acta Crystallographica Section C (2019) 75, 5
a=21.0988(13)Å b=8.4322(5)Å c=12.0341(8)Å
α=90° β=99.505(2)° γ=90°
Benzoylmetronidazole--maleic acid (1/1)
C13H14N3O4,C4H3O4
Acta Crystallographica Section C (2019) 75, 5
a=43.130(3)Å b=5.7944(4)Å c=15.2645(11)Å
α=90° β=109.600(3)° γ=90°
Benzoylmetronidazole--3-aminobenzoic acid (1/1)
C13H13N3O4,C7H7NO2
Acta Crystallographica Section C (2019) 75, 5
a=7.9316(7)Å b=11.9585(12)Å c=12.1978(12)Å
α=76.362(3)° β=78.927(3)° γ=79.583(3)°
Benzoylmetronidazole--salicylic acid (1/1)
C13H13N3O4,C7H6O3
Acta Crystallographica Section C (2019) 75, 5
a=9.5055(6)Å b=31.2239(19)Å c=6.8578(4)Å
α=90° β=102.628(2)° γ=90°
Benzoylmetronidazole--isophthalic acid (1/1)
C13H13N3O4,C8H6O4
Acta Crystallographica Section C (2019) 75, 5
a=8.8300(3)Å b=33.7182(10)Å c=7.3199(2)Å
α=90° β=107.8780(10)° γ=90°
Benzoylmetronidazole--2,6-dihydroxybenzoic acid (1/1)
C13H14N3O4,C7H5O4
Acta Crystallographica Section C (2019) 75, 5
a=8.2443(4)Å b=15.9009(7)Å c=15.4526(8)Å
α=90° β=102.454(2)° γ=90°
Benzoylmetronidazole--malonic acid (4/1)
2(C13H13N3O4),0.5(C6H4O8)
Acta Crystallographica Section C (2019) 75, 5
a=26.1542(4)Å b=7.27080(10)Å c=16.6719(3)Å
α=90° β=90° γ=90°
Benzoylmetronidazole--resorcinol (2/1)
2(C13H13N3O4),C6H6O2
Acta Crystallographica Section C (2019) 75, 5
a=26.3241(4)Å b=7.16120(10)Å c=33.8433(5)Å
α=90° β=90° γ=90°
Nevirapine butanol 0.3-solvate
C15H14N4O,0.3C4H10O
Acta Crystallographica Section E (2008) 64, 1 o292-o292
a=7.8116(6)Å b=8.4302(7)Å c=12.5451(11)Å
α=84.817(5)° β=88.415(5)° γ=68.252(4)°
Caesium lithium sulfate
Cs1.15Li2.85(SO4)2
Acta Crystallographica Section C (2003) 59, 7 i67-i70
a=5.0620(2)Å b=5.2230(3)Å c=16.0060(9)Å
α=90.00° β=90.00° γ=90.00°
Caesium lithium rubidium sulfate
Cs0.90Li2.88Rb0.22(SO4)2
Acta Crystallographica Section C (2003) 59, 7 i67-i70
a=5.0530(2)Å b=5.1990(4)Å c=15.9840(8)Å
α=90.00° β=90.297(3)° γ=90.00°
Estra-1,3,5(10)-triene-3,17-diol(17?)-17-pentanoate
C23H32O3
Crystal Growth & Design (2014) 14, 11 5700
a=7.3706(2)Å b=19.8583(5)Å c=13.9888(3)Å
α=90° β=90.619(2)° γ=90°
Estra-1,3,5(10)-triene-3,17-diol(17?)-17-pentanoate
C23H32O3
Crystal Growth & Design (2014) 14, 11 5700
a=7.5539(12)Å b=18.667(3)Å c=14.092(2)Å
α=90° β=90.402(8)° γ=90°
Diethylcarbamazine citrate
C10H22N3O,C6H7O7
Crystal Growth & Design (2010) 10, 7 3094
a=13.8050(3)Å b=10.2581(2)Å c=13.9890(3)Å
α=90.00° β=93.689(2)° γ=90.00°
Diethylcarbamazine citrate
C6H7O7,C10H22N3O
Crystal Growth & Design (2010) 10, 7 3094
a=13.915(2)Å b=10.096(2)Å c=14.089(3)Å
α=90.0000° β=103.56(1)° γ=90.0000°
Diethylcarbamazine citrate
C10H22N3O,C6H7O7
Crystal Growth & Design (2010) 10, 7 3094
a=27.4386(7)Å b=10.1644(2)Å c=14.0536(3)Å
α=90.00° β=95.033(1)° γ=90.00°
Diethylcarbamazine citrate
C10H22N3O,C6H7O7
Crystal Growth & Design (2010) 10, 7 3094
a=13.656(5)Å b=10.259(5)Å c=13.902(6)Å
α=90.140(3)° β=95.389(3)° γ=92.677(3)°
Didanosine
C10H12N4O3,0.125H2O
Crystal Growth & Design (2010) 10, 4 1885
a=7.277(1)Å b=10.052(2)Å c=14.476(3)Å
α=90.000° β=93.71(1)° γ=90.000°
Hexagram-Type Topology Lamivudine Duplex
3(C8H11N3O3S),2(H2O)
Crystal Growth & Design (2012) 12, 10 5138
a=14.550(1)Å b=14.550(1)Å c=29.538(3)Å
α=90.00° β=90.00° γ=120.00°
Lamivudine hemihydrochloride hemihydrate
C8H12N3O3S,C8H11N3O3S,H2O,Cl
Crystal Growth & Design (2012) 12, 10 5138
a=6.972(5)Å b=12.167(7)Å c=13.867(8)Å
α=100.52(3)° β=93.15(4)° γ=91.43(4)°
Maleate of 5-FC
C8H8FN3O5
Crystal Growth & Design (2013) 13, 10 4315
a=9.3450(5)Å b=11.8620(6)Å c=18.9540(8)Å
α=90° β=113.573(3)° γ=90°
Fumarate monohydrate of 5-FC
C6H8F1N3O4
Crystal Growth & Design (2013) 13, 10 4315
a=3.550(5)Å b=9.093(5)Å c=24.527(5)Å
α=90.000(5)° β=91.737(5)° γ=90.000(5)°
Oxalate of 5-FC
C5H5FN3O3
Crystal Growth & Design (2013) 13, 10 4315
a=5.2610(2)Å b=15.1970(6)Å c=7.8840(3)Å
α=90° β=92.206(3)° γ=90°
C7H3Cl2O2,C3H10NO
C7H3Cl2O2,C3H10NO
CrystEngComm (2017)
a=12.16200(10)Å b=7.94030(10)Å c=25.8738(2)Å
α=90° β=90° γ=90°
C6H8N3O,NO3
C6H8N3O,NO3
CrystEngComm (2016) 18, 34 6378
a=6.3630(13)Å b=15.970(6)Å c=8.043(2)Å
α=90° β=92.151(16)° γ=90°
Benzoylmetronidazole--3,5-dihydroxybenzoic acid (3/1)
3(C13H13N3O4),C7H6O4
Acta Crystallographica Section C (2019) 75, 5
a=7.1481(2)Å b=36.7892(8)Å c=18.0584(4)Å
α=90° β=100.4510(10)° γ=90°
Rankamaite
Al0.6K1.26Na2.22Nb1.29O31Ta9.11
American Mineralogist (2011) 96, 1455-1460
a=17.224Å b=17.687Å c=3.9361Å
α=90° β=90° γ=90°